Nasdaq
RTTNews) – Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton’s tyrosine kinase or BTK, in patients with relapsed/refractory Waldenström’s macroglobuli…
Read More
Nurix Reports Positive Results For BTK Degrader NX-5948 In Waldenstrom’s Macroglobulinemia
RTTNews
11:26
RTTNews) – Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton’s tyrosine kinase or BTK, in patients with relapsed/refractory Waldenström’s macroglobuli…
